Sally struthers returns

@prosperousguy @DeuceCabooseSki Fintel

@Dancingtapas @DeuceCabooseSki What Is the actual short of float on $IOVA? What site do you go to, to check it, that you Trust? TIA

Cost to borrow average on $IOVA a week ago was .84%. Today it is 1.06%. Subtle but she held $5 today. Watch CTB.

@prosperousguy @seahorse_anton It was just an old one that they renewed.

@seahorse_anton The $IOVA chart is surprisingly good, because on June 18th they filed a $89.65 million ATM and no selloff for those fearing an almost near term dilution.

$IOVA holding well today. Any drop towards 4.40 to 4.6, I will add.

@whygeniusfails I added a bit today when I get some cash soon adding heavily.

$GLSI all this did was significantly reduce trial risk. I think it will be one and done at 1st interim…..but this hedges incase he needs lower p value….allows randomized arms to continue to enroll past 500…..market will wake up to see this is a HUGE win. If not, big pharma will. 85% success in 1st interim…..read the release carefully. Higher on 2nd. How do you think he calculated 85%….triangulated the data. Wake up. lol

**Best-case TAM for GLSI-100 (GP2) if Ph3 wins + full FDA/EU approval:** Greenwich LifeSciences targets HLA-A*02+ HER2+ breast cancer patients after standard HER2 therapy to prevent recurrence. - Eligible pool: ~44k–210k patients/year (US + EU) per company data. - Ph2b signal: 80%+ reduction in recurrences (near 100% DFS in completers vs ~89% placebo for HER2 3+). **Optimistic scenario (all stars align):** Strong Ph3 data, broad label, solid uptake, pricing aligned with advanced HER2 agents (~$50-150k/course for 11 doses over 3 yrs). → **Peak annual sales potential: $1B–$3B+ globally.** TAM (full capture) much larger, but realistic blockbuster territory if it becomes adjuvant standard. High binary risk. DYOR, biotech speculation.

Greenwich LifeSciences, Inc $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is making major strides in the fight against breast cancer. Its lead immunotherapy candidate, GLSI-100, is now in a global Phase III trial (FLAMINGO-01), spanning 150 sites across the U.S. and Europe, targeting up to 750 HER2+ breast cancer patients. Why This Matters to Investors: • Breakthrough Potential: Aims to reduce recurrence rates by over 80%, outperforming current HER2 therapies. • Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes required. • Global Validation: Backed by elite research groups across the U.S. and EU. bit.ly/4muX8cl $GLSI $PFE $LLY $JNJ $NVS $AZN $PBYI $BNTX $MRK $HOLX $IMCR

@sidecarcap $GLSI with almost 50% Insider ownership. That is skin in the game

$IOVA still in this with shares. but seems to be losing a bit of momentum. bull flag perhaps? gotta close above 5

$IOVA 🚨 Iovance is gaining attention as investors focus on Amtagvi commercialization and improving fundamentals. 2026 revenue guidance: $350M–$370M Cash runway expected into 2028. The next catalyst: sales growth + pipeline expansion. 🧬📈 #Biotech #CancerTherapy

For 13 years, Professor Matheus taught art. Then he gave his students a lesson they would never forget. Together, they collected thousands of plastic bottle caps and turned them into a giant mural called “A Última Tampinha” (The Last Bottle Cap). Projects like this remind us why recycling matters. Every plastic bottle cap, can, or piece of paper that gets reused means less waste in landfills, less pollution, and fewer natural resources being used.

He told his students to go to the windows. Get out. Jump if you have to. Then Liviu Librescu walked to the classroom door and pressed his body against it. He was 76 years old. He weighed 140 lbs The gunman was in the hallway. It was April 16, 2007. A Monday morning. Solid mechanics class at Virginia Tech, Room 204. Twenty-two students, most of them 19 or 20 years old. At 9:45 AM, gunshots echoed through Norris Hall. Room by room, the shooter was working his way down the corridor. Liviu heard it. He understood immediately. He had survived the Holocaust. He had survived a labor camp. He had spent decades living under Communist oppression. He knew exactly what evil sounded like. He told his students to escape through the windows. Second floor — it was a drop, but they'd survive. Then he walked to the door and held it shut with his body. The shooter tried to force it open. It wouldn't move. He fired through the door. Wood splintered. Bullets came through. Liviu stayed. Behind him, students were climbing out the windows. Dropping to the ground. Running. One by one, all twenty-two of them got out. The shooter kept firing through the door. Liviu held it shut until every student was safe. Then the bullets killed him. When police arrived, they found his body at the door. All 22 of his students survived. Not one was injured. Liviu Librescu was born on August 18, 1930, in Ploiești, Romania. He was Jewish. In 1941, when he was eleven years old, Romanian authorities sent him and his family to a labor camp. His father died there. Liviu survived. When the war ended, he was fifteen. He went back to school. Studied engineering. Earned a doctorate from the University of Bucharest. But Communist Romania had no interest in allowing a Jewish intellectual to succeed. He was blocked from academic positions. Passed over for jobs he deserved. He applied to emigrate. The government kept refusing. Finally, in 1978 when Liviu was 48 years old — Israeli Prime Minister Menachem Begin personally intervened. Romania let him go. He had spent most of his adult life trapped in a country that didn't want him. In Israel, he taught at Tel Aviv University. Published over 300 papers. Became an international expert in aeroelasticity — the science of how air flows over aircraft wings. In 1985, Virginia Tech offered him a position. He moved to Blacksburg, Virginia. He taught there for 22 years. His students loved him — demanding but kind, high standards, genuine care. He was still teaching full-time at 76. Still publishing research. Still showing up every Monday morning for solid mechanics. April 16 was the first day of Passover — the Jewish holiday celebrating liberation from slavery and oppression. Liviu Librescu died on the day his tradition sets aside to celebrate freedom. He spent his entire life escaping death and oppression by luck, by persistence, by the intervention of others. And on his last morning, he chose to stand at a door so that twenty-two young people could have the future he had fought so hard to reach. He could have run. He could have hidden. He could have climbed out a window with his students. He chose to stay. The Virginia Tech shooting killed 32 people that day — the deadliest school shooting in American history at the time. Room 204 had zero casualties. Because a 76-year-old Holocaust survivor held a door with his body until every student behind him was gone. His funeral was held in Israel. Students from Virginia Tech flew across the ocean to honor him. The Israeli government awarded him the Star of David Medal posthumously. Virginia Tech named a scholarship in his memory. His son said his father died the way he lived — protecting others. A man who survived everything evil threw at him for 76 years. On his last day, he made sure 22 kids survived too. Professor Liviu Librescu. August 18, 1930 — April 16, 2007. Holocaust survivor. Labor camp survivor. 302 published papers. 22 years at Virginia Tech. 22 students out the window. He held the door.

@kainvests the jobsite tell is real but i'd read it as label expansion, not a pending action. you staff EMA, UK, switzerland and NSCLC reg roles when you're building a multi region commercial machine. hiring leads the filing calendar by a year. throughput and LUN-202 are what you staff for

$IOVA Iovance Biotherapeutics seems to be hiring more regulatory talent. Why? A few possibilities: 1. Normal turnover and backfilling open roles. 2. Building out the team for EMA and UK resubmission work, and maybe Switzerland too. 3. Laying the groundwork for future label expansion, including NSCLC (IOV-LUN-202) and first-line Melanoma (TILVANCE-301). Base, bear or bullish? Base (BAU = Business As Usual) and undoubtedly bullish. We saw what happened with the EMA submission. Hiring the right people and professionalising Iovance's regulatory team - already strong with Marc R. Theoret, former FDA Deputy Centre Director (trial.medpath.com/news/iovance-b…) - is nothing but bullish. Whether this hints that the NSCLC data is good or not is a different story, and this does not represent supporting evidence. Slowly but surely, we are getting there, and that's what matters.

@ChartLearning @crypto_biotech Yep that's all it is but that doesn't factor in sudden partnership sending this to the moon.

@crypto_biotech I believe the sell off is now due to data coming later than sooner $glsi

$GLSI The negative or muted price reaction today is much more about market (retail & shorts) misunderstanding and typical biotech volatility than any fundamental problem with the update. 4 slides. Beautiful opportunity to add. This will go over $100:

Adam Feuerstein at STAT News has made a career out of relentlessly attacking $NWBO. The “objective journalist” label doesn’t hold up when you hear what actual biotech professionals and investors say about your coverage once they’re off the record at conferences. You can publish whatever narrative you want online. But reputation is what people say about you when you’re not in the room. The mask tends to slip when the professionals start talking candidly. 🤡

@crypto_biotech Why do you think they punished it so badly. I take this news as very good.

$GLSI Exactly. I see interim by end of year max. I predicted last week after PR that we would have more soon as that’s what they’ve done in the past. Extrapolate from This current gap longer side of his historical pattern of Insider Buying…which is the best Insider Buys:

@whygeniusfails @ChartLearning @crypto_biotech I agree for the most part, assuming they are at /around 14 events, we will need 14 more before 1st interim. Even with enrollment rate doubling we are still talking next year for read out on interim one.